Cohort Event Monitoring of Adverse Reactions to COVID-19 Vaccines in Seven European Countries: Pooled Results on First Dose-Reference-Cited by-同舟云学术

Cohort Event Monitoring of Adverse Reactions to COVID-19 Vaccines in Seven European Countries: Pooled Results on First Dose

Published:2023-04 Issue:4 Volume:46 Page:391-404
ISSN:0114-5916
Container-title:Drug Safety
language:en
Short-container-title:Drug Saf

Author:

Raethke Monika^ORCID,van Hunsel Florence^ORCID,Thurin Nicolas H.^ORCID,Dureau-Pournin Caroline^ORCID,Mentzer Dirk,Kovačić Barbara,Mirošević Skvrce Nikica,De Clercq Evelien,Sabbe Martine^ORCID,Trifirò Gianluca^ORCID,Luxi Nicoletta,Giovanazzi Alexia,Shakir Saad,Klungel Olaf H.,Schmikli Sandor,Sturkenboom Miriam^ORCID

Funder

European Medicines Agency

the Agency for Medicinal Products and Medical Devices of Croatia

Paul-Ehrlich-Institut

Ministère de la Santé et des Solidarités and the Ministère de l’Enseignement supérieur, de la Recherche et de l’Innovation

Ministerie van Volksgezondheid, Welzijn en Sport

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,Toxicology

Link

https://link.springer.com/content/pdf/10.1007/s40264-023-01281-9.pdf

Reference28 articles.

1. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383(27):2603–15. https://doi.org/10.1056/NEJMoa2034577.

2. Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397(10269):99–111. https://doi.org/10.1016/S0140-6736(20)32661-1.

3. McDonald I, Murray SM, Reynolds CJ, Altmann DM, Boyton RJ. Comparative systematic review and meta-analysis of reactogenicity, immunogenicity and efficacy of vaccines against SARS-CoV-2. NPJ Vaccines. 2021;6(1):74. https://doi.org/10.1038/s41541-021-00336-1.

4. European Medicines Agency (EMA). SmPC Comirnaty. 2022. https://www.ema.europa.eu/en/documents/product-information/comirnaty-epar-product-information_en.pdf Accessed 14 July 2022.

5. Dhanda S, Osborne V, Lynn E, Shakir S. Postmarketing studies: can they provide a safety net for COVID-19 vaccines in the UK? BMJ Evid Based Med. 2022;27(1):1–6. https://doi.org/10.1136/bmjebm-2020-111507.

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A review of the scientific literature on experimental toxicity studies of COVID-19 vaccines, with special attention to publications in toxicology journals;Archives of Toxicology;2024-09-03

2. Cohort event monitoring of safety of COVID-19 vaccines: the Italian experience of the “ilmiovaccinoCOVID19 collaborating group”;Frontiers in Drug Safety and Regulation;2024-08-12

3. What is the Safety of COVID-19 Vaccines in Immunocompromised Patients? Results from the European “Covid Vaccine Monitor” Active Surveillance Study;Drug Safety;2024-06-22

4. Frequency and timing of adverse reactions to COVID-19 vaccines; A multi-country cohort event monitoring study;Vaccine;2024-04

5. Safety Monitoring of COVID-19 Vaccines in Persons with Prior SARS-CoV-2 Infection: A European Multi-Country Study;Vaccines;2024-02-26